aTyr Pharma Details New Phase 3 Plan for Efzofitimod, Targets 372 Patients with FDA-Backed Endpoints
ATYR sits 42% above its 52-week low of $0.395 on elevated volume (2.0× avg).
Summary
aTyr Pharma has outlined the detailed design for its new Phase 3 study (C-006) for efzofitimod, targeting approximately 372 patients with restrictive pulmonary sarcoidosis. The plan incorporates insights from the prior EFZO-FIT study and FDA Type C meeting feedback, with FVC (Forced Vital Capacity) as the primary endpoint. This provides a concrete path forward for the company's lead drug after its previous Phase 3 failure in March and the termination of the Kyorin partnership in May. The company also reported $68.3M in cash as of March 31, 2026, providing crucial runway for the trial. An IND filing for the C-006 study is planned for June 2026.
At the time of this announcement, ATYR was trading at $0.56 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $53.6M. The 52-week trading range was $0.40 to $7.29. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Wiseek News.